PH-231

About Phio Pharmaceuticals

Phio Pharmaceuticals is a clinical-stage biotech company leveraging its proprietary INTASYL self-delivering siRNA platform to develop next-generation immuno-oncology therapies. Founded on Nobel laureate Craig Mello's RNAi discovery, the company has pivoted from discovery to development, advancing lead candidates PH-762 (PD-1 silencer) and PH-894 (BRD4 silencer) through early clinical trials. Its strategy focuses on overcoming delivery challenges in RNAi to enhance immune cell function and directly attack tumors, aiming to create synergistic treatments for cancers like cutaneous squamous cell carcinoma and melanoma.

Therapeutic Areas